Published in BMC Pharmacol on June 22, 2012
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem (1976) 903.81
Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol (1973) 47.81
Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care (2004) 9.16
Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry (1999) 8.04
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology (2003) 3.35
Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature (1976) 2.85
Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet (2002) 2.77
5-HT2CRs expressed by pro-opiomelanocortin neurons regulate energy homeostasis. Neuron (2008) 2.04
Modern antipsychotic drugs: a critical overview. CMAJ (2005) 1.98
Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenet Genomics (2005) 1.97
Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. Eur Psychiatry (2005) 1.75
From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci U S A (2007) 1.74
Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms. Pharmacol Ther (2009) 1.48
Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus. Drug Metab Pharmacokinet (2005) 1.32
The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull (1989) 1.31
Dopamine D2 receptors as treatment targets in schizophrenia. Clin Schizophr Relat Psychoses (2010) 1.29
Involvement of hypothalamic histamine H1 receptor in the regulation of feeding rhythm and obesity. Diabetes (2004) 1.25
New antipsychotics and schizophrenia: a review on efficacy and side effects. Curr Med Chem (2004) 1.22
Potential mechanisms of atypical antipsychotic-induced metabolic derangement: clues for understanding obesity and novel drug design. Pharmacol Ther (2010) 1.21
Clozapine and olanzapine, but not conventional antipsychotics, increase insulin release in vitro. Eur Neuropsychopharmacol (2004) 1.11
Atypical antipsychotic agents: a critical review. Am J Health Syst Pharm (2000) 1.08
Second-generation antipsychotics for schizophrenia: a review of clinical pharmacology and medication-associated side effects. Isr J Psychiatry Relat Sci (2005) 1.07
The relationship of pharmacology to side effects. J Clin Psychiatry (1997) 1.05
Bodyweight change as an adverse effect of drug treatment. Mechanisms and management. Drug Saf (1996) 1.04
Extrapyramidal side effects of antipsychotic treatment: scope of problem and impact on outcome. Ann Clin Psychiatry (2002) 1.01
Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability. Drugs (2008) 1.00
Effects of dopamine D1 and dopamine D2 antagonists on the free feeding and drinking patterns of rats. Behav Neurosci (1991) 0.95
Olanzapine-induced weight gain in the rat: role of 5-HT2C and histamine H1 receptors. Psychopharmacology (Berl) (2009) 0.94
Weight change and atypical antipsychotic treatment in patients with schizophrenia. J Clin Psychiatry (2001) 0.93
Atypical antipsychotics: new drugs, new challenges. Cleve Clin J Med (2007) 0.92
The hypothalamic H1 receptor: a novel therapeutic target for disrupting diurnal feeding rhythm and obesity. Trends Pharmacol Sci (2006) 0.90
4-Piperazinyl-10H-thieno[2,3-b][1,5]benzodiazepines as potential neuroleptics. J Med Chem (1980) 0.89
Blockade of 5-HT2a receptors reduces haloperidol-induced attenuation of reward. Neuropsychopharmacology (2006) 0.89
Influence of 5-HT2C receptor and leptin gene polymorphisms, smoking and drug treatment on metabolic disturbances in patients with schizophrenia. Br J Psychiatry (2008) 0.87
Strain-dependent neurochemical and neuroendocrine effects of desipramine, but not fluoxetine or imipramine, in spontaneously hypertensive and Wistar-Kyoto rats. Neuropharmacology (2000) 0.85
Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents. J Med Chem (2004) 0.84
Structural contributions of antipsychotic drugs to their therapeutic profiles and metabolic side effects. J Neurochem (2011) 0.83
Association of adiponectin and metabolic syndrome among patients taking atypical antipsychotics for schizophrenia: a cohort study. Schizophr Res (2009) 0.81
Dietary induced anorexia: a review of involvement of the histaminergic system. J Am Coll Nutr (1996) 0.80
Quetiapine reverses altered locomotor activity and tyrosine hydroxylase immunoreactivity in rat caudate putamen following long-term haloperidol treatment. Neurosci Lett (2007) 0.80
Olanzapine: a critical review of recent literature. Expert Opin Pharmacother (2005) 0.78
An exploration of the effect of modafinil on olanzapine associated weight gain in normal human subjects. Biol Psychiatry (2008) 0.78
Novel atypical antipsychotic agents: rational design, an efficient palladium-catalyzed route, and pharmacological studies. J Med Chem (2005) 0.78
Effect of typical and atypical neuroleptics on the behavioural consequences of activation by muscimol of mesolimbic and nigro-striatal dopaminergic pathways in the rat. Psychopharmacology (Berl) (1991) 0.77
[Body weight changes and psychotropic drug treatment: neuroleptics]. Encephale (2001) 0.77
Molecular field analysis of clozapine analogs in the development of a pharmacophore model of antipsychotic drug action. J Mol Graph Model (2001) 0.77
Histamine and the neuroregulation of food intake. Nutrition (1997) 0.77
In vitro cytotoxicity evaluation of some substituted isatin derivatives. Bioorg Med Chem (2006) 2.15
Cannabidiol potentiates Δ⁹-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats. Psychopharmacology (Berl) (2011) 1.84
Investigation of m1/m4 muscarinic receptors in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression disorder. Neuropsychopharmacology (2004) 1.65
An investigation into the cytotoxicity and mode of action of some novel N-alkyl-substituted isatins. J Med Chem (2007) 1.57
N-phenethyl and N-naphthylmethyl isatins and analogues as in vitro cytotoxic agents. Bioorg Med Chem (2008) 1.56
Short- and long-term effects of antipsychotic drug treatment on weight gain and H1 receptor expression. Psychoneuroendocrinology (2008) 1.50
Effects of dietary fat types on body fatness, leptin, and ARC leptin receptor, NPY, and AgRP mRNA expression. Am J Physiol Endocrinol Metab (2002) 1.47
Reducing olanzapine-induced weight gain side effect by using betahistine: a study in the rat model. J Psychopharmacol (2012) 1.47
Decreased density of serotonin 2A receptors in the superior temporal gyrus in schizophrenia--a postmortem study. Prog Neuropsychopharmacol Biol Psychiatry (2009) 1.43
The signal pathways in azoxymethane-induced colon cancer and preventive implications. Cancer Biol Ther (2009) 1.34
Arcuate NPY controls sympathetic output and BAT function via a relay of tyrosine hydroxylase neurons in the PVN. Cell Metab (2013) 1.33
High-fat diet exposure increases dopamine D2 receptor and decreases dopamine transporter receptor binding density in the nucleus accumbens and caudate putamen of mice. Neurochem Res (2007) 1.21
Alkaloids from the roots of Stemona aphylla. J Nat Prod (2009) 1.21
Insulin caused drug resistance to oxaliplatin in colon cancer cell line HT29. J Gastrointest Oncol (2011) 1.15
Evaluation of an ethnopharmacologically selected Bhutanese medicinal plants for their major classes of phytochemicals and biological activities. J Ethnopharmacol (2011) 1.10
Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia. Exp Brain Res (2006) 1.08
Effects of olanzapine on muscarinic M3 receptor binding density in the brain relates to weight gain, plasma insulin and metabolic hormone levels. Eur Neuropsychopharmacol (2011) 1.05
A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice. Int J Neuropsychopharmacol (2009) 1.03
Oat beta-glucan increases postprandial cholecystokinin levels, decreases insulin response and extends subjective satiety in overweight subjects. Mol Nutr Food Res (2009) 1.01
Density of metabotropic glutamate receptors 2 and 3 (mGluR2/3) in the dorsolateral prefrontal cortex does not differ with schizophrenia diagnosis but decreases with age. Schizophr Res (2011) 0.99
Decreased density of muscarinic receptors in the superior temporal gyrusin schizophrenia. J Neurosci Res (2005) 0.98
Increased density of GABAA receptors in the superior temporal gyrus in schizophrenia. Exp Brain Res (2005) 0.98
High-fat diet decreases tyrosine hydroxylase mRNA expression irrespective of obesity susceptibility in mice. Brain Res (2009) 0.97
Ethnobotanical authentication and identification of Khrog-sman (Lower Elevation Medicinal Plants) of Bhutan. J Ethnopharmacol (2011) 0.96
Synthesis of carbocyclic hydantocidins via regioselective and diastereoselective phosphine-catalyzed [3 + 2]-cycloadditions to 5-methylenehydantoins. J Org Chem (2005) 0.96
Alterations of muscarinic and GABA receptor binding in the posterior cingulate cortex in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry (2006) 0.96
Early brain development disruption from NMDA receptor hypofunction: relevance to schizophrenia. Brain Res Rev (2006) 0.96
Metabotropic glutamate receptor 5 binding and protein expression in schizophrenia and following antipsychotic drug treatment. Schizophr Res (2013) 0.96
The role of histaminergic H1 and H3 receptors in food intake: a mechanism for atypical antipsychotic-induced weight gain? Prog Neuropsychopharmacol Biol Psychiatry (2009) 0.95
The molecular mechanisms underpinning the therapeutic properties of oleanolic acid, its isomer and derivatives for type 2 diabetes and associated complications. Mol Nutr Food Res (2014) 0.94
Developmental vitamin D deficiency alters MK-801-induced behaviours in adult offspring. Psychopharmacology (Berl) (2011) 0.93
Gender differences in cognitive function of patients with chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry (2012) 0.93
Examining the pathways linking chronic sleep restriction to obesity. J Obes (2010) 0.92
Membrane phospholipid composition, alterations in neurotransmitter systems and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry (2005) 0.92
Phenylpropanoids and furanocoumarins as antibacterial and antimalarial constituents of the Bhutanese medicinal plant Pleurospermum amabile. Nat Prod Commun (2014) 0.92
Obese reversal by a chronic energy restricted diet leaves an increased Arc NPY/AgRP, but no alteration in POMC/CART, mRNA expression in diet-induced obese mice. Behav Brain Res (2009) 0.92
GC/GC-MS analysis, isolation and identification of bioactive essential oil components from the Bhutanese medicinal plant, Pleurospermum amabile. Nat Prod Commun (2013) 0.91
Synthesis and biological activities of conformationally restricted cyclopentenyl-glutamate analogues. J Org Chem (2002) 0.91
A new protoberberine alkaloid from Meconopsis simplicifolia (D. Don) Walpers with potent antimalarial activity against a multidrug resistant Plasmodium falciparum strain. J Ethnopharmacol (2013) 0.90
An assessment of the Bhutanese traditional medicine for its ethnopharmacology, ethnobotany and ethnoquality: Textual understanding and the current practices. J Ethnopharmacol (2013) 0.89
Antipsychotic treatment and neuregulin 1-ErbB4 signalling in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry (2011) 0.89
The role of hypothalamic H1 receptor antagonism in antipsychotic-induced weight gain. CNS Drugs (2013) 0.89
Phytochemical studies on Stemona burkillii prain: two new dihydrostemofoline alkaloids. J Nat Prod (2004) 0.88
Olanzapine treatment and metabolic dysfunction: a dose response study in female Sprague Dawley rats. Behav Brain Res (2010) 0.88
Activation of signal pathways and the resistance to anti-EGFR treatment in colorectal cancer. J Cell Biochem (2010) 0.88
Oat beta-glucan supplementation does not enhance the effectiveness of an energy-restricted diet in overweight women. Br J Nutr (2009) 0.88
Antimalarial alkaloids from a Bhutanese traditional medicinal plant Corydalis dubia. J Ethnopharmacol (2012) 0.88
Inhibition of TNF-α production in LPS-activated THP-1 monocytic cells by the crude extracts of seven Bhutanese medicinal plants. J Ethnopharmacol (2013) 0.88
Phytochemical and biological activity studies of the Bhutanese medicinal plant Corydalis crispa. Nat Prod Commun (2012) 0.88
Binaphthyl-based dicationic peptoids with therapeutic potential. Angew Chem Int Ed Engl (2010) 0.88
The effects of diets enriched in beta-glucans on blood lipoprotein concentrations. J Clin Lipidol (2009) 0.88
Second generation antipsychotic-induced type 2 diabetes: a role for the muscarinic M3 receptor. CNS Drugs (2013) 0.87
Insulin decreases therapeutic efficacy in colon cancer cell line HT29 via the activation of the PI3K/Akt pathway. Curr Drug Discov Technol (2011) 0.87
High dose of simvastatin induces hyperlocomotive and anxiolytic-like activities: The association with the up-regulation of NMDA receptor binding in the rat brain. Exp Neurol (2008) 0.87
Simvastatin prevents dopaminergic neurodegeneration in experimental parkinsonian models: the association with anti-inflammatory responses. PLoS One (2011) 0.87
The effects of antipsychotics on the density of cannabinoid receptors in the dorsal vagal complex of rats: implications for olanzapine-induced weight gain. Int J Neuropsychopharmacol (2008) 0.87
No changes in densities of cannabinoid receptors in the superior temporal gyrus in schizophrenia. Neurosci Bull (2007) 0.87
Serum levels of polyunsaturated fatty acids are low in Chinese men with metabolic syndrome, whereas serum levels of saturated fatty acids, zinc, and magnesium are high. Nutr Res (2012) 0.86
Reciprocal signalling between NR2 subunits of the NMDA receptor and neuregulin1 and their role in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry (2011) 0.86
Chemical constituents and antioxidant and biological activities of the essential oil from leaves of Solanum spirale. Nat Prod Commun (2012) 0.85
Aripiprazole differentially affects mesolimbic and nigrostriatal dopaminergic transmission: implications for long-term drug efficacy and low extrapyramidal side-effects. Int J Neuropsychopharmacol (2009) 0.85
Transmembrane domain Nrg1 mutant mice show altered susceptibility to the neurobehavioural actions of repeated THC exposure in adolescence. Int J Neuropsychopharmacol (2012) 0.85
Stemofoline ethyl acetate solvate. Acta Crystallogr Sect E Struct Rep Online (2009) 0.85
Phytochemical studies on Stemona plants: isolation of stemofoline alkaloids. J Nat Prod (2005) 0.85
Structural revision of stemoburkilline from an E-alkene to a Z-alkene. J Nat Prod (2009) 0.84
AM 251 and beta-Funaltrexamine reduce fat intake in a fat-preferring strain of mouse. Behav Brain Res (2007) 0.84
Distinct neurobehavioural effects of cannabidiol in transmembrane domain neuregulin 1 mutant mice. PLoS One (2012) 0.84
Decreased plasma peptide YY accompanied by elevated peptide YY and Y2 receptor binding densities in the medulla oblongata of diet-induced obese mice. Endocrinology (2007) 0.84
Teasaponin reduces inflammation and central leptin resistance in diet-induced obese male mice. Endocrinology (2013) 0.83
Asymmetric synthesis of (-)-swainsonine, (+)-1,2-di-epi-swainsonine, and (+)-1,2,8-tri-epi-swainsonine. J Org Chem (2002) 0.83
Alterations to melanocortinergic, GABAergic and cannabinoid neurotransmission associated with olanzapine-induced weight gain. PLoS One (2012) 0.83
Structural contributions of antipsychotic drugs to their therapeutic profiles and metabolic side effects. J Neurochem (2011) 0.83
Ionotropic glutamate receptor binding in the posterior cingulate cortex in schizophrenia patients. Neuroreport (2005) 0.83
Semisynthesis and acetylcholinesterase inhibitory activity of stemofoline alkaloids and analogues. J Nat Prod (2010) 0.82
Perinatal phencyclidine treatment alters neuregulin 1/erbB4 expression and activation in later life. Eur Neuropsychopharmacol (2011) 0.82
Neuregulin-1 signalling and antipsychotic treatment: potential therapeutic targets in a schizophrenia candidate signalling pathway. Psychopharmacology (Berl) (2013) 0.82
Excitatory and inhibitory neurotransmission is chronically altered following perinatal NMDA receptor blockade. Eur Neuropsychopharmacol (2009) 0.81
Inter-meal interval is increased in mice fed a high whey, as opposed to soy and gluten, protein diets. Appetite (2008) 0.81
G protein-coupled receptor 12 deficiency results in dyslipidemia and obesity in mice. Biochem Biophys Res Commun (2006) 0.81
Copper-mediated cyclization-halogenation and cyclization-cyanation reactions of beta-hydroxyalkynes and o-alkynylphenols and anilines. J Org Chem (2010) 0.80
Synthesis and antibacterial studies of binaphthyl-based tripeptoids. Part 1. Bioorg Med Chem (2010) 0.80
Synthesis of (+)-uniflorine a: a structural reassignment and a configurational assignment. Org Lett (2008) 0.80
Carbon nanotube nanoweb-bioelectrode for highly selective dopamine sensing. ACS Appl Mater Interfaces (2011) 0.80
Synthesis and antibacterial studies of binaphthyl-based tripeptoids. Part 2. Bioorg Med Chem (2010) 0.80
Differential expression of hypothalamic CART mRNA in response to body weight change following different dietary interventions. Neurochem Int (2008) 0.80
Perinatal administration of PCP alters adult behaviour in female Sprague-Dawley rats. Behav Brain Res (2007) 0.80
Altered dopamine receptor and dopamine transporter binding and tyrosine hydroxylase mRNA expression following perinatal NMDA receptor blockade. Neurochem Res (2008) 0.80
Synthesis of novel N-protected hydrophobic phenylalanines and their application in potential antibacterials. Eur J Med Chem (2008) 0.80
Semisynthesis and biological activity of stemofoline alkaloids. J Nat Prod (2009) 0.80
Increases in peptide Y-Y levels following oat beta-glucan ingestion are dose-dependent in overweight adults. Nutr Res (2009) 0.79
Alterations in 5-HT2A receptor binding in various brain regions among 6-hydroxydopamine-induced Parkinsonian rats. Synapse (2010) 0.79
A static handgrip method for distal quantitative sweat measurements. Neurosci Lett (2007) 0.79
Synthesis of hyacinthacine B3 and purported hyacinthacine B7. Chem Commun (Camb) (2009) 0.79
Total synthesis of uniflorine A, casuarine, australine, 3-epi-australine, and 3,7-di-epi-australine from a common precursor. J Org Chem (2010) 0.79
Olanzapine treatment decreases the density of muscarinic M2 receptors in the dorsal vagal complex of rats. Prog Neuropsychopharmacol Biol Psychiatry (2007) 0.79
Inhibition of P-glycoprotein mediated multidrug resistance by stemofoline derivatives. Chem Pharm Bull (Tokyo) (2013) 0.79
Synthesis and antibacterial activity of C2-symmetric binaphthyl scaffolded amino acid derivatives. Eur J Med Chem (2011) 0.78
Sequential 1,4- and 1,2-addition reactions to α,β-unsaturated N-acyliminium ions: a new strategy for the synthesis of spiro and bridged heterocycles. Org Lett (2013) 0.78
Immunohistochemical localisation of the NK1 receptor in the human amygdala: preliminary investigation in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry (2006) 0.78